Dendrite Aligns with Oracle to Enhance Pharmaceutical Clinical Trial Efficiency

Dendrite Aligns with Oracle to Enhance Pharmaceutical Clinical Trial Efficiency

Business Editors

MORRISTOWN, N.J.–(BUSINESS WIRE)–Feb. 21, 2002

Dendrite (NASDAQ/NMS: DRTE), the visionary innovator in global pharmaceutical technology, today announced it is working with Oracle, the world’s largest enterprise software company, to provide on-site support services for the Oracle Remote Data Capture product for clinical trials.

During clinical trials, pharmaceutical companies contract with doctors in hospitals and research organizations to act as clinical investigators. These investigators recruit patients who are appropriate for the trial and collect medical data on these patients over a series of visits. Today, approximately 95 percent of this medical data is collected on paper. Using Oracle Remote Data Capture, this data can now be collected electronically at the source to help dramatically reduce the delays and errors associated with paper-based processes.

Dendrite will provide global support services at investigative sites using Oracle Remote Data Capture. Dendrite will test and validate all computer hardware for clinical investigators and provide complete on-site and web-based training for clinical site personnel. In addition, Dendrite will provide 24×7, multilingual help desk support for staff at investigative sites, providing front-line support for hardware, communications, and usage issues.

Oracle will provide full help desk support for Oracle RDC software issues. Oracle Consulting will continue to provide implementation, training, validation, and software services for the pharmaceutical companies.

“The proper recording of data is essential to ensure the success of any clinical trial; however, the traditional use of paper has led to potential errors and costly delays,” said William Van Nostrand, Senior Vice President of Dendrite’s Clinical Trial Services Division. “Dendrite and Oracle are now providing a more efficient web-based solution for all clinical trial remote data capture needs.”

“The integrated Oracle Clinical/RDC product, which uses a unified clinical database, is dramatically more efficient than using multiple applications and databases for remote data capture,” said Sohaib Abbasi, Senior Vice President of Oracle’s tools division. “Dendrite’s services will help streamline the deployment, training, and hotline support at investigative sites. Together, we can provide a low-risk, high-value solution to pharmaceutical customers.”

About Dendrite

Dendrite, the visionary innovator in global pharmaceutical technology, helps pharmaceutical clients strategically manage customer relationships to increase market share. For more information, visit www.dendrite.com.

About Dendrite Clinical Trial Services

By supporting and facilitating eClinical solutions for the pharmaceutical industry, Dendrite’s Clinical Trial Services Division streamlines and supports eClinical processes such as patient randomization, electronic and mobile data capture, document management, worldwide serious adverse event reporting, and investigator coordination through its global multilingual 24×7 help desk. The Division also optimizes protocols and identifies ideal investigators and sites using Dendrite’s proprietary data and analytic engines. In addition, the Division facilitates and manages the eLearning process by providing Application Sharing of eClinical solutions for investigators, clinical research coordinators, and clinical research associates.

Media Inquiries

Bob Brody

Ogilvy Public Relations Worldwide

212-880-5248

Bob.Brody@ogilvypr.com

Dendrite is a registered trademark of Dendrite International, Inc. Oracle is a registered trademark of Oracle Corporation. Other names may be trademarks of their respective owners.

The foregoing contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The statements may be identified by such forward-looking terminology as “expect,” “believe,” “may,” “will,” “intend,” “plan,” and similar statements or variations. Such forward-looking statements are based on our current estimates and assumptions and involve certain significant risks and uncertainties, including: risks associated with and dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy selling cycles, product implementation cycles, customer budget cycles, and timing of revenue recognition; dependence on major customers; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; retention of key senior managers; and unique characteristics of the consumer packaged goods industry. Other important factors that should be considered are included in the company’s 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements.

COPYRIGHT 2002 Business Wire

COPYRIGHT 2002 Gale Group